New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 21, 2013
08:54 EDTMNKDSummer Street 'much more optimistic' about MannKind approval
After speaking with a former FDA reviewer, Summer Street said it is "much more optimistic" that current trials of MannKind's inhalable insulin for treating type 1 and type 2 diabetes could lead to FDA approval. Summer Street said the consultant it spoke to sees an 85% chance that in the type 1 diabetes study Afrezza hits its endpoint. Shares of MannKind are up 13c to $6.83 in pre-market trading.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
05:52 EDTMNKDStocks with implied volatility movement; MNKD LOCO
Subscribe for More Information
05:39 EDTMNKDMannKind, Sanofi on track to launch Afrezza in Q1, says Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use